Project Grant R21CA306070
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $410K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- The University of California, San Diego (UCSD) was awarded a $551,207.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to research a new therapeutic target to prevent pancreatic cancer metastasis. The 3-year grant period runs from July 1, 2023 to June 30, 2026. The project aims to investigate medical solutions for the battlefield by transforming health care through innovative and impactful research in areas like cancer...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- This Cooperative Agreement awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,281,520.00 in funding to The Leland Stanford Junior University to conduct research on the fundamental biological mechanisms of cancer metastasis, organ tropism, and immune evasion. The project aims to integrate genetic barcoding with single-cell profiling to uncover the key molecular drivers underlying metastatic fitness and diverse cancer cell states in pancreatic ductal...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $571,350.00 in funding to the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The award supports research aimed at developing metabolic interventions to halt the progression of pancreatic cancer. SBP, an independent non-profit biomedical research organization, will leverage advanced technologies and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Miami to support research into a novel immunotherapy approach for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a can regulate T cell exhaustion and restore anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC), which has a very low 5-year survival rate of 12%. The research will utilize the KPC mouse model of PDAC...
- This $151,263 federal Project Grant award was provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program to fund a research project titled "Understanding Paracrine Interactions Induced by Morphogens in PDAC" at The Trustees of Columbia University in the City of New York. The project aims to identify how active morphogen signaling shapes local immunosuppression in the pancreatic tumor microenvironment by studying the interactions between malignant...
- This $642,755 Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research by The Institute for Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting the trogocytosis process that enables cancer-associated fibroblasts to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells. The research aims to elucidate how ANO6 activity is regulated in the...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower), aims to investigate the impact of CDK4/6 inhibition on the progression of intraductal papillary mucinous neoplasia (IPMN), a precursor to pancreatic ductal adenocarcinoma (PDAC). The $166,037.00 grant, awarded on April 1, 2025, will support research at the University of California, San Diego (UCSD) to determine the effects of CDK4/6 inhibition on IPMN tumor progression and the...